Novo Eyes Global-First Japan Approval For Concizumab
First Filing For Hemophila A/B Candidate
Novo Nordisk has filed for the approval of its hemophilia A/B contender concizumab in Japan, which could become the first market globally for the TFPI inhibitor. The company sees dosing convenience as a potential strong advantage in the market, where there are relatively few options for hemophilia B available.
